{"organizations": [], "uuid": "77d32f028a4be59b6888ead32a70587a9ff5723a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180404.html", "section_title": "Archive News &amp; Video for Wednesday, 04 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-eleven-biotherapeutics-reports-q4/brief-eleven-biotherapeutics-reports-q4-loss-per-share-0-22-idUSASC09UY6", "country": "US", "domain_rank": 408, "title": "BRIEF-Eleven Biotherapeutics Reports Q4 Loss Per Share $0.22", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.251, "site_type": "news", "published": "2018-04-05T04:26:00.000+03:00", "replies_count": 0, "uuid": "77d32f028a4be59b6888ead32a70587a9ff5723a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-eleven-biotherapeutics-reports-q4/brief-eleven-biotherapeutics-reports-q4-loss-per-share-0-22-idUSASC09UY6", "ord_in_thread": 0, "title": "BRIEF-Eleven Biotherapeutics Reports Q4 Loss Per Share $0.22", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eleven biotherapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4 (Reuters) - Eleven Biotherapeutics Inc:\n* ELEVEN BIOTHERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING RESULTS AND VICINIUM DEVELOPMENT PROGRESS\n* Q4 LOSS PER SHARE $0.22 * ELEVEN BIOTHERAPEUTICS - NO REV WAS RECOGNIZED DURING QTR ENDED DEC. 31, 2017 VS $0.8 MLN FOR SAME THREE-MONTH PERIOD IN 2016\n* ELEVEN BIOTHERAPEUTICS INC - EXPECTS TO HAVE CAPITAL TO FUND CURRENT OPERATING PLANS INTO Q1 2019\n* ELEVEN BIOTHERAPEUTICS INC - CASH AND CASH EQUIVALENTS WERE $14.7 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-05T04:26:00.000+03:00", "crawled": "2018-04-05T17:24:57.013+03:00", "highlightTitle": ""}